Volume 9, Number 12—December 2003
Research
Multidrug-resistant Mycobacterium tuberculosis in HIV-Infected Persons, Peru
Pablo E. Campos*†, Pedro G. Suarez‡§, Jorge Sanchez†, David Zavala‡, Jorge Arevalo‡, Eduardo Ticona‡, Charles M. Nolan*¶, Thomas M. Hooton*, and King K. Holmes*
Table 2
Drug-susceptibility profiles of Mycobacterium tuberculosis isolates from participants with and without known HIV infectiona
| Characteristic | HIV positive |
HIV negative or unknown status |
|
|---|---|---|---|
| Patients |
Interviewed patients |
All patients |
|
| N (%) | N (%) | N (%) | |
| Total no. tested for drug resistance |
81 (100) |
108 (100) |
965 (100) |
| Fully susceptible isolates |
28 (35) |
92 (85) |
789 (82) |
| Any resistance |
52 (65) |
16 (15) |
76 (18) |
| Any H resistance |
42 (52) |
11 (10) |
110 (10) |
| Any R resistance |
39 (48) |
2 (2) |
53 (6) |
| Any E resistance |
19 (24) |
0 (0) |
27 (3) |
| Any S resistance |
39 (48) |
12 (11) |
88 (9) |
| Any Z resistance |
28 (35) |
NA |
NA |
| Multidrug resistance |
35 (43) |
1 (1) |
38 (3.9) |
| Only HR resistance |
3 (4) |
NA |
NA |
| HRZ resistance |
25 (32) |
NA |
NA |
| HRESZ resistance | 11 (14) | NA | NA |
aNA, not available; H, isoniazid; R, rifampin; E, ethambutol; S, streptomycin; Z, pyrazinamide; HRZ resistance includes any strain resistant at least to H and R and Z.
Page created: February 07, 2011
Page updated: February 07, 2011
Page reviewed: February 07, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.